Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

The medication, known as sodium-glucose co-transporter 2 inhibitors (SGLT2is), is already used to lower blood sugar in people ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...